Autologous stem cell transplantation after high-dose melphalan for the treatment with multiple myeloma has resulted in prolonged progression-free survival and overall survival in patients under 65 years. We have examined the role of autologous transplantation in 17 patients with multiple myeloma over 65 years at our centre using a matched pair analysis with younger patients. The median age of this cohort of patients over 65 years was 67 years (65-74) and their outcome and transplant-related morbidity was compared with 17 younger pair mates with a median age of 55 years (31-64). Sixteen patients received high-dose melphalan, and one received busulphan with autologous stem cell rescue. The high-dose therapy was well tolerated in both elderly patients and the matched pairs, with comparable time to recover neutrophils and platelets. Treatmentrelated mortality also did not differ significantly in both the groups. Median overall survival of the elderly patients was 3.59 years similar to 3.01 years of the pair mates (P = 0.92). Autologous stem cell transplantation after high-dose melphalan conditioning was equally well tolerated in groups of patients above and below 65 years. There was no difference in relapse rate, OS and myelotoxicity in both the groups. These findings suggest that advanced age should not be an exclusion criterion from autologous transplant programmes. Bone Marrow Transplantation (2000) 25, 533-539. Keywords: autologous; transplantation; elderly; myeloma Multiple myeloma is a disease of the elderly with a median age of onset of 65 years; the conventional treatment approach in this group of patients is a combination of melphalan and prednisolone.
year age group, rising to 60.7 per 100 000 in the 85 years and over group. In females, the incidence is 14.3 per 100 000 at 65-69 years, rising to 29.9 in the 85 years and over group. 2, 3 This rise in age-related incidence justifies reevaluation of current therapies including high-dose chemotherapy and autologous stem cell rescue for more elderly patients.
A dose response effect for melphalan has been demonstrated in multiple myeloma. Doses of 140 mg/m 2 without stem cell support, higher doses of melphalan at 200 mg/m 2 with stem cell support and tandem transplants have been associated with increased complete remission (CR) rates, increased event-free survival (EFS) and an increase in overall survival (OS). [4] [5] [6] [7] A recent randomized trial 7 showed a survival advantage for patients less than 65 years undergoing high-dose melphalan treatment, and this benefit is recognised by health care purchasers now paying for such treatment for people less than 65 years (Geoffrey Carroll, North Thames Purchasing Consortium, personal communication).
Recently, transplant-related mortality (TRM) has decreased considerably due to prompt neutrophil recovery with peripheral blood stem cells rescue (PBSC) 8 so that it can now be considered whether this treatment can be offered to individuals with myeloma over the age of 65 years. These patients have previously been excluded from high-dose programmes purely on the basis of age, but meet all the other prerequisites.
A recent study by Siegel et al 9 has examined the feasibility of treating patients between 65 and 76 years with high-dose melphalan 200 mg/m 2 and concluded that this treatment was well tolerated in terms of medullary and extramedullary toxicities.
We have assessed a similar group of patients to determine if these results can be confirmed. This study compares patient tolerance of first autologous transplant in 17 individuals aged over 65 years with 17 patients under 65 years matched for type of treatment and prognostically relevant pre-treatment variables.
Patients and methods

Patients
The Royal Marsden prospective research database for multiple myeloma was used to identify 514 patients with multiple myeloma seen between March 1987 and March 1998, of whom 303 had had no previous treatment (NPT) and 211 had been previously treated (PT). At presentation, 75 patients (47 NPT and 28 PT) were over 65 years, increasing to 107 patients reaching the age of 65 at last follow-up. Out of these 107 patients, 66 (45 NPT and 21 PT) were treated at some stage and this denominator of patients was the basis for a matched paired analysis of the 407 patients in the database aged less than 65 years. Forty patients received infusional chemotherapy in the form of VAMP/CVAMP (see below), of whom 13 went on to receive high-dose chemotherapy and an autograft (10 NPT and 3 PT); eight had received low-dose cyclophosphamide; 13 oral melphalan-prednisolone (MP); four had had highdose melphalan with an autograft (all had PT) and one had had ABCM. 10 . Thus, 17 patients (10 NPT and 7 PT) over the age of 65 years were identifiable who received highdose chemotherapy and an autograft.
All the autografts were preceded by induction chemotherapy as described below. Characteristics of the 17 elderly patients are detailed in Table 1 . Two of these (Nos 3 and 5) had their autograft at first relapse. The first patient had received CVAMP initially followed by interferon (IFN) maintenance and the second had received oral MP (described below) followed by IFN maintenance at diagnosis.
All patients gave written informed consent according to standard hospital policy.
Treatment Induction chemotherapy:
11 VAMP consisted of vincristine 0. 4 Oral melphalan prednisolone (MP) consisted of melphalan at a dose of 10 mg once a day × 7 days and prednisolone 40 mg p.o. once a day × 7 days.
One patient received intravenous cyclophosphamide as induction.
High-dose treatment: Approximately 6 weeks after the start of the last chemotherapy cycle, patients received highdose melphalan (200 mg/m 2 infused over 30 min) on day −1 if the glomerular filtration rate was Ͼ40 ml/min 5 as determined by 51 Cr EDTA. Adequate hydration before and after high dose treatment with melphalan (n = 16) was ensured to maintain a urine output of 20 ml/min for 1 h after the high-dose, and 500 ml/h over the subsequent 2 h. In patients with poor renal function, busulphan (n = 1) was used at a dose of 16 mg/kg, given at 1 mg/kg, 6 hourly p.o. for 4 days.
Stem cell transplants:
According to hospital policy, until November 1992, patients received bone marrow autografts (ABMT) with marrow harvested 6 weeks after completion of induction chemotherapy if the marrow aspirate showed Ͻ30% infiltration by plasma cells. Subsequently, patients received peripheral blood stem cells (PBSC) mobilized approximately 6 weeks after the last chemotherapy cycle 5, 12 using recombinant human granulocyte colony-stimulating factor (rhG-CSF) (Amgen, Thousand Oaks, CA, USA) and all patients were eligible for harvest regardless of the degree of marrow infiltration with plasma cells. All harvests were undertaken as an outpatient procedure using the Cobe separator (Cobe, Denver, CO, USA). Stem cells were stored following controlled cooling with 5% dimethylsulphoxide (DMSO) at −179°C in the vapour phase of liquid nitrogen. When required, stem cells were rapidly thawed to 37°C and reinfused into the patient immediately without further processing. o. days 1-7 then tapered over 7 days) or no treatment. 13 One patient received UKALL X intensification (No. 9).
Post high-dose consolidation:
Maintenance interferon (IFN):
After high-dose treatment, patients were planned to start maintenance interferon alpha2b (3 megaunits/m 2 3 × weekly, s.c., Schering Plough, Welwyn Garden City, UK) initially as part of a randomised trial 14, 15 and subsequently in all patients when the WBC count reached at least 2 × 10 9 /l and platelet count at least 50 × 10 9 /l. The interferon dose was adjusted according to toxicity.
14,15
Criteria for response
We used the same criteria for response as previously described. 16 Four criteria had to be met for a patient to be regarded as having achieved complete remission CR: (1) no paraprotein measurable by scanning densitometry of serum proteins separated on a cellulose acetate membrane by electrophoresis and stained with Ponceau S and immunofixed with Nigrosin; 17, 18 (2) no detectable Bence Jones proteinuria on electrophoresis of neat urine stained with colloidal gold and immunofixed with Nigrosin; (3) 5% or fewer plasma cells of normal morphology on bone marrow aspiration; and (4) criteria 1-3 had to be fulfilled for at least 3 months without evidence of extramedullary disease. Patients were designated as having achieved a partial response (PR) if there was a 50% decrease in measurable paraprotein (IgG or IgA myeloma) or bone marrow infiltration (non-secretory or Bence Jones myeloma) which was sustained for a month or more.
Assessment of toxicity
Toxicity was assessed according to the WHO grading and variables analysed in the matched pairs and the elderly patients during their first autograft were: days of hospitalisation, hematologic toxicity, renal (serum creatinine), hepatic (bilirubin, alanine and aspartate transaminases, cardiotoxicity and sepsis).
Statistical considerations
Analysis was undertaken in June 1999. Patient characteristics at presentation were compared using the Chi-square test for categoric data and the Kruskal-Wallis 19 nonparametric test for numeric data.
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Overall survival (OS) and event-free survival (EFS) were compared using the life table method of Kaplan and Meier 20 and the log rank test. 21 .
Selection of matched controls
The 17 matched control patients were selected by using inhouse computer routines similar to minimum distance casecontrol matching, ie a Euclidian distance measure method. 22 The matched pairs were comparable (in order of importance) for type of autograft (PBSC or ABMT), for subtype of myeloma, stage at diagnosis, disease status at transplant, days from original diagnosis to autograft, infusional chemotherapy before transplant and ␤ 2 M.
Results
Demography
Patient characteristics are detailed in Table 2 gives the details of presentation variables among the elderly and the matched controls. The time lag between diagnosis and the autograft was 14 months (range, 4-56) in the elderly and 7 months (range, 5-66) in the matched controls (P = 0.2). Two patients in both the groups had their autograft at relapse. Seven of 17 were PT in the elderly group and eight of 17 were PT in the pair mates (P = 1).
Comparison with matched controls
Induction therapy
Three patients received VAMP, 11 C-VAMP, one VAD, one MP and one received i.v. cyclophosphamide. The median number of courses of infusional chemotherapy (n = 15) was five, in both the elderly patients (range, 3-7) and the younger pair mates (range, 1-6).
High-dose treatment
Sixteen patients received conditioning with melphalan and one received busulphan. Fourteen patients received PBSC and three ABMT. The median mononuclear cell dose returned was 3.46 × 10 6 /kg (2.37-6.18) in the elderly patients and 4 × 10 6 /kg (1.9-9.14) in the matched pairs.
Interferon maintenance
Thirteen of 14 patients alive post high-dose started IFN at a median of 3 months (range, 1.4-5). One patient did not start as he relapsed 4 months after high-dose therapy and died of progressive disease (PD) 5 months later. Elderly vs matched patients (median values or numbers).
Toxicity during autograft
Neutropenia: All patients had grade III-IV neutropenia and the median number of days for neutrophil recovery to Ͼ0.5 × 10 9 /l was 17 (range, [16] [17] [18] [19] [20] [21] [22] [23] [24] in the elderly patients and 20 (range, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] in the matched pairs (P = 0.82) (Figure 1) .
Thrombocytopenia:
The median number of days to recovery of platelets to more than 50 × 10 9 /l was 35 (range, 24-55) in patients over 65 years compared to 24 (range, 17-42) in the pair mates (P = 0.16) (Figure 2 ).
Days of hospitalisation:
The median number of days of hospitalisation in the elderly patients during autografting was 19 (range, 17-23) compared to 22 (range, 18-27) in the matched pairs (P = 0.92) (Figure 3) . Sepsis/renal/hepatic/cardiotoxicity: Nine of 17 elderly patients and six of 17 pair mates had grade III-IV sepsis (P = 0.5). None of the patients developed grade III-IV renal toxicity. One patient in the elderly group developed grade III hepatotoxicity (No. 15) and died on day +30 due to fulminant septicaemia and fungaemia. Three patients among the elderly group developed cardiotoxicity with two of them developing atrial fibrillation (Nos 1 and 15 ). In the pair mates two also had atrial fibrillation and one had acute left ventricular failure and died on day +52.
Response
Post-induction chemotherapy: After induction chemotherapy four of 17 (23.5%) patients attained CR, nine (52.9%) were in PR and four (23.5%) were NR in the elderly group, while five of 17 (29.5%) attained CR, eight (47%) PR and four (23.5%) were NR in the matched controls.
Post high-dose: Post high-dose treatment the total number of patients in CR was six of 17 (35.3%) in patients у65 years compared to eight of 17 (47%) among the pair mates (P = 0.7). In the elderly group 8/17 (47%) were in PR and three (17.6%) died (see below).
Treatment-related mortality (TRM):
Among the elderly patients, three of 17 (17.6%) died, one from staphylococcal septicaemia on day +82, one from bacterial septicaemia and pulmonary aspergillosis on day +30, and the third patient (No. 5) died on day +11 from left ventricular failure and progressive disease. This patient had compromised left ventricular function due to a history of an anterior myocardial infarction with an ejection fraction of 34% prior to highdose therapy and had aggressive disease with soft tissue plasmacytomas in the retroorbital space, in the lacrimal glands, right kidney and pancreatic areas. Among the pair mates, two of 17 (11.7%) of patients died; one died of PD and septicaemia on day +15 while the second died on day +52 of left ventricular failure, while she was in partial remission. Treatment-related mortality was not significantly different within the two groups (P = 1). Relapse post high-dose: Eight patients relapsed after their first high-dose therapy at a median of 24 months (range, 4-60 months), and of these, four patients received a second PBSC autograft. Three of the four died at day +80 (circulating plasmablasts, progressive disease No. 7), day + 412 (of PD, No. 8) and day +18 (aggressive PD with pathological fracture of the wrist and radius, No. 14) post second high-dose and one patient continues to be in PR post second high-dose (No. 12). There was one TRM among the second autografts.
Discussion
We have previously shown that for patients under the age of 70 years an intensive sequential treatment programme of infusional chemotherapy with VAMP, followed by highdose melphalan and stem cell rescue, and maintenance interferon, 8 in 195 unselected patients produced a complete remission rate of 53% in the total group, and of 74% in those who received an autologous transplant. This translated into a median duration of survival of 4.5 years and event-free survival of 25 months. Age, renal function, poor performance status, compromised cardiac or pulmonary function and psychological problems precluded the use of high-dose treatment in this group of patients, but over 50% of the new patients who entered into the study received a transplant. These benefits have been formally tested in a randomised controlled trial from Western France by Attal et al who showed that patients less than 65 years undergoing autotransplantation for myeloma had a survival advantage. 7 Healthcare purchasers recognise this as standard treatment and fund such treatment for patients below 65 years in the UK (Geoffrey Carroll, North Thames Purchasing
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Consortium, personal communication and BSBMT Guidelines). However, because treatment-related mortality for high-dose melphalan for patients under 65 years has dropped from an initial 17% 22 to less than 3% 8 probably due to the use of peripheral blood stem cell transplants rather than autologous marrow, 12 it is now possible to undertake this treatment so easily that in certain centres in the US high-dose melphalan is being given as out-patient treatment, resulting in significant financial savings. 23 The obvious question now is whether this treatment can be safely given to an older group of patients with multiple myeloma. It has already been shown in older patients with active myeloma receiving conventional chemotherapy (median age 71, range 65-92) that advanced age should not be considered a major obstacle to active treatment. 24 We have undertaken this analysis with a view to evaluating the role of the more intensive autologous transplantation for the treatment of multiple myeloma in patients over the age of 65 years, and compared it with matched pairs in the younger age group. The response rate, eventfree survival, overall survival, transplant-related morbidity, and mortality were the same as seen in younger patients.
The age distribution of the 17 patients in this study consisted mostly of patients towards the younger end of the 65-74 years age range, 10 of 17 patients being less than 67 years. This reflects our median age for the whole group of myeloma patients (n = 514) in our experience who have an age range of 21-89 years (median 52 years), which is younger than other published series and was due to the fact that we had a cut-off policy of not taking patients over the age of 70 years for our original sequential therapy programme. 8 However, towards the end of this period we relaxed our acceptance criteria and now recruit older patients into intensive chemotherapy programmes. Of interest, only one of the 10 patients less than 68 years of age died which is not different from the two deaths that occurred in the seven patients who were older (P = 0.4). One of the patients in the older age group who died had compromised cardiac function but was autografted because of aggressive soft tissue and bone disease. The overall survival in patients less than 68 years was 3.6 years (range less than 11 days -more than 4.9 years) vs 1.3 years (range less than 29 days -more than 9.7 years) in the older patients and was not significantly different.
We were concerned that the number of patients in this pilot study was small, but in fact it is sufficient to show that this treatment is not significantly more toxic.
Comparing our results to a similar study published by Siegel et al 9 in 49 patients aged over 65 years, it appears that the complete remission rate attained in our patients after a single transplant (6/17, 35.3%) was higher compared to that after double autotransplants (10/49, 20%) which could be due to the longer follow-up in our patients. The recruitment of the first patient in our series was done 2.5 years before the Siegel study and one of the patients more than 67 years of age at the time of his first autograft has been alive and well for almost 10 years now.
The OS and EFS were 3.5 years and 2.03 years in our study and may be slightly better than the outcome of the Siegel study (3.3 years and 1.5 years, respectively), perhaps due to a better CR rate attained in our subset of patients after autografting.
Neutrophil and platelet recovery were 17 days and 35 days in our study after the first transplant compared with 11 days and 15 days respectively, in the Siegel study possibly due to the use of bone marrow autografts (n = 2), previous chemotherapy received by seven patients, and autografting at first relapse in two patients in our cohort.
Treatment-related mortality in their study was 4/49 (8%) compared with 2/17 (11%) in our group within 60 days after the first high-dose (P = 0.8) which is not significantly different.
Sixty-nine percent of patients in the 65-69 years age group and 50% of those above 70 years proceeded to a second autograft in their group with no transplant-related mortality. Four of eight patients who relapsed in our group received a second autograft and one of the four died.
Palumbo et al 25 have also recently evaluated the safety and efficacy of repeated doses of melphalan 100 mg/m 2 at days 30, 90 and 150 with stem cell support compared with melphalan and prednisolone and have demonstrated its superiority in terms of response rate and clinical outcome both in younger (median age 54, range 38-58), and elderly patients (median age 64, range 55-75) using a pair mate analysis, but the intermediate doses of melphalan used in their study were different from the doses in our protocol.
The above two studies and our study show that highdose therapy produces clinical benefit with acceptable morbidity and mortality not materially different from the now well established cost effective benefit seen in younger patients, in which the cost per week of life gained with autotransplantation is better than that achieved after conventional chemotherapy. 26 We recommend that the age range for patients being offered this treatment should now be extended up to the age of 74 years with further work undertaken to determine the role of such treatments for even older patients.
